BioSyent BIOYF Stock
BioSyent Price Chart
BioSyent BIOYF Financial and Trading Overview
BioSyent stock price | 7.14 USD |
Previous Close | 5.39 USD |
Open | 5.39 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 5.39 - 5.39 USD |
52 Week Range | 4.69 - 6.34 USD |
Volume | 2K USD |
Avg. Volume | 3.1K USD |
Market Cap | 65.36M USD |
Beta (5Y Monthly) | 0.791245 |
PE Ratio (TTM) | 17.966665 |
EPS (TTM) | 0.43 USD |
Forward Dividend & Yield | 0.12 (2.20%) |
Ex-Dividend Date | June 1, 2023 |
1y Target Est | N/A |
BIOYF Valuation Measures
Enterprise Value | 40.28M USD |
Trailing P/E | 17.966665 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.3878648 |
Price/Book (mrq) | 1.9507781 |
Enterprise Value/Revenue | 1.472 |
Enterprise Value/EBITDA | 6.185 |
Trading Information
BioSyent Stock Price History
Beta (5Y Monthly) | 0.791245 |
52-Week Change | -8.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.34 USD |
52 Week Low | 4.69 USD |
50-Day Moving Average | 5.62 USD |
200-Day Moving Average | 5.49 USD |
BIOYF Share Statistics
Avg. Volume (3 month) | 3.1K USD |
Avg. Daily Volume (10-Days) | 1.8K USD |
Shares Outstanding | 12.09M |
Float | 9.43M |
Short Ratio | N/A |
% Held by Insiders | 40.77% |
% Held by Institutions | 1.31% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.08 |
Trailing Annual Dividend Yield | 1.48% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.1975 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 18.43% |
Operating Margin (ttm) | 22.87% |
Gross Margin | 82.57% |
EBITDA Margin | 23.79% |
Management Effectiveness
Return on Assets (ttm) | 10.21% |
Return on Equity (ttm) | 15.41% |
Income Statement
Revenue (ttm) | 27.37M USD |
Revenue Per Share (ttm) | 2.24 USD |
Quarterly Revenue Growth (yoy) | -7.90% |
Gross Profit (ttm) | 22.86M USD |
EBITDA | 6.51M USD |
Net Income Avi to Common (ttm) | 5.05M USD |
Diluted EPS (ttm) | 0.3 |
Quarterly Earnings Growth (yoy) | -26.00000000000000000000000000000000% |
Balance Sheet
Total Cash (mrq) | 26.25M USD |
Total Cash Per Share (mrq) | 2.17 USD |
Total Debt (mrq) | 1.35M USD |
Total Debt/Equity (mrq) | 4.05 USD |
Current Ratio (mrq) | 9.017 |
Book Value Per Share (mrq) | 2.763 |
Cash Flow Statement
Operating Cash Flow (ttm) | 3.96M USD |
Levered Free Cash Flow (ttm) | 2.59M USD |
Profile of BioSyent
Country | United States |
State | ON |
City | Mississauga |
Address | 2476 Argentia Road |
ZIP | L5N 6M1 |
Phone | 905-206-0013 |
Website | https://www.biosyent.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Q&A For BioSyent Stock
What is a current BIOYF stock price?
BioSyent BIOYF stock price today per share is 7.14 USD.
How to purchase BioSyent stock?
You can buy BIOYF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioSyent?
The stock symbol or ticker of BioSyent is BIOYF.
Which industry does the BioSyent company belong to?
The BioSyent industry is Drug Manufacturers-Specialty & Generic.
How many shares does BioSyent have in circulation?
The max supply of BioSyent shares is 11.26M.
What is BioSyent Price to Earnings Ratio (PE Ratio)?
BioSyent PE Ratio is 16.60465000 now.
What was BioSyent earnings per share over the trailing 12 months (TTM)?
BioSyent EPS is 0.43 USD over the trailing 12 months.
Which sector does the BioSyent company belong to?
The BioSyent sector is Healthcare.